Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476839 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
A Phase 1 study of Recurrent Adult Hodgkin Lymphoma, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01476839 is a Phase 1 study of Recurrent Adult Hodgkin Lymphoma that has completed, run by City of Hope Medical Center. The registered enrollment target is 25 participants, below the 29-participant average among 4 other Recurrent Adult Hodgkin Lymphoma trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01476839, a Phase 1 study of Recurrent Adult Hodgkin Lymphoma, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I clinical trial studies the side effects and best dose of radiolabeled monoclonal antibody therapy when given together with combination chemotherapy before stem cell transplant and to see how well it works in treating patients with primary refractory (did not respond to treatment) or relapsed (returned after treatment) Hodgkin lymphoma. Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carmustine, etoposide, cytarabine, and melphalan (BEAM), work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or stopping them from spreading. Giving radiolabeled monoclonal antibody therapy together with combination chemotherapy may kill more cancer cells
Conditions Studied
Interventions
- DRUG etoposide
- DRUG melphalan
- DRUG carmustine
- DRUG cytarabine
- BIOLOGICAL basiliximab
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-11-09 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01476839
The ClinicalTrials.gov registry entry for NCT01476839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 29-participant average among 4 other Recurrent Adult Hodgkin Lymphoma trials with a reported enrollment target (14% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Adult Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which etoposide is the first listed.
NCT01476839 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01476839 about?
NCT01476839 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma". This phase I clinical trial studies the side effects and best dose of radiolabeled monoclonal antibody therapy when given together with combination chemotherapy before stem cell transplant and to see how well it works in treating patients with primary refractory (did not respond to treatment) or rel...
What is the current status of trial NCT01476839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-11-09. Estimated completion is 2024-05-31.
What conditions does trial NCT01476839 study?
This clinical trial studies the following conditions: Recurrent Adult Hodgkin Lymphoma.
What interventions are being tested in trial NCT01476839?
The interventions under investigation include: etoposide (DRUG), melphalan (DRUG), carmustine (DRUG), cytarabine (DRUG), basiliximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01476839?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01476839 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
COMPLETED · Phase 1
-
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
COMPLETED · Phase 2
-
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.